Clinical trials: Type 2 Diabetes Mellitus With Metabolic Syndrome
Diabetes Mellitus, Type 2, Overweight and Obesity
The Metabolic Impact of Intermittent Carbohydrate Restriction in Individuals With Type 2 Diabetes
The primary aim of this randomized cross-over intervention study is to investigate the effect of four weeks of intermittent carbohydrate restriction (alternating between two days of normal dietary intake and two days of…
- Conditions
- Diabetes Mellitus, Type 2, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- INTERCARB (NCT06144593)
- Testing
- Dietary macronutrient composition
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- Hvidovre University Hospital
Celiac Disease
Assessment of Coeliac Disease in Patients With Type 2 Diabetes
This study aims to screen and diagnose coeliac disease in patients with type 2 diabetes and monitor the effect of gluten-free diet on the metabolic status
- Trial name
- NCT06283264
- Volunteers
- 100 people
- Sponsor
- Assiut University
Metabolic Syndrome, Albuminuria
Dietetic Intervention With Soluble Fiber in Type 2 Diabetes Mellitus (DM) Patients With Metabolic Syndrome (MS)
Metabolic Syndrome (MS) is an clinical condition with high cardiovascular risk. More than 80% of DM patients had MS. Dietary factors can be associated to both, DM and MS.
- Trial name
- NCT01071785
- Testing
- guar gum
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Diabetes Mellitus, Type 2, Obesity
Influence of a Liquid Oat Bran Product on Blood Glucose in Patients With Poorly Controlled Type 2 Diabetes
This study evaluates the effects of an ad libitum addition of a high fiber product to the regular diet of type 2 diabetes patients on body weight and blood sugar control.
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Overweight, Metabolic Syndrome
- Trial name
- NCT03805802
- Testing
- active product, reference product
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Stoffwechselzentrum Rhein - Pfalz
Type 2 Diabetes Mellitus (T2DM), Obesity (Disorder)
Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy
The goal of this clinical trial is to learn whether adding the NutriSteppe digital dietary intervention to routine medical care improves metabolic health in adults aged 21 to 65 years with type 2 diabetes mellitus, obesity, or…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Obesity (Disorder), Overweight, Metabolic Syndrome
- Trial name
- NutriSteppe (NCT07728669)
- Testing
- NutriSteppe Digital Dietary Intervention
- Where
- Kazakhstan
- Volunteers
- 120 people
- Sponsor
- Kazakh Academy of Nutrition
Diabetes Mellitus
Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes
The purpose of this study is to determine the efficacy of pioglitazone and metformin combination therapy, once daily (QD), on glycosylated hemoglobin in adults with type 2 diabetes.
- Trial name
- NCT00754403
- Testing
- Pioglitazone and metformin, Metformin
- Volunteers
- 312 people
- Sponsor
- Takeda
Lipidemia, Type 2 Diabetes (T2DM)
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as…
- Conditions
- Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
- Trial name
- RUBENS (NCT07219602)
- Testing
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg
- Where
- 55 sites in United States, Czechia and 2 more
- Volunteers
- 300 people
- Sponsor
- NewAmsterdam Pharma
Aerobic Exercise, Strength Training
Home-Based Circuit Training in Overweight/Obese Older Adult Patients With Knee Osteoarthritis and Type 2 Diabetes
Background: Obesity and type 2 diabetes mellitus (T2DM) are considered two of the most prevalent metabolic diseases linked to the onset of knee pain caused by osteoarthritis.
- Conditions
- Aerobic Exercise, Strength Training, Glycemic Control, Blood Pressure
- Trial name
- NCT06309654
- Testing
- 12-week home-based circuit training (HBCT), Standard of care (CONT)
- Where
- Saudi Arabia
- Volunteers
- 70 people
- Sponsor
- Princess Nourah Bint Abdulrahman University
Type2 Diabetes Mellitus
Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus
Ficus deltoidea leaves, Cinnamomum cassia and Black seed powdered extract have long been used for the treatment of type 2 diabetes mellitus.
- Trial name
- NCT05343767
- Testing
- Natural Wellness Low-Glu low dose, Natural Wellness Low-Glu high dose, Metformin
- Where
- Egypt
- Volunteers
- 198 people
- Sponsor
- Natural Wellness Egypt
Sleep Apnea, Obstructive, Type 2 Diabetes Mellitus
Effect of Oral Appliance Therapy on Glucose Levels in Patients With T2DM and OSA: A Pilot Trial
This study will evaluate the impact on blood glucose of the use of an oral appliance to treat obstructive sleep apnea (OSA) in individuals with Type 2 diabetes.
- Trial name
- NCT03167684
- Testing
- Oral appliance therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Diabetes Mellitus Type 2
GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes
Obstructive Sleep Apnea (OSA) and type 2 diabetes mellitus are two prevalent medical conditions with significant associated cardiovascular and cerebrovascular morbidity and mortality.
- Trial name
- NCT00509223
- Testing
- Positive Airway Pressure therapy, Lifestyle counseling
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 416 people
- Sponsor
- ResMed
Sleep Apnea Syndrome (OSAS)
Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea
Semaglutide (a GLP-1RA) is approved for type 2 diabetes mellitus T2DM and obesity, but its effect on obstructive sleep apnea OSA remains unclear.
- Trial name
- NCT07281196
- Testing
- Semaglutide Subcutaneous Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Fengxian District Central Hospital
Diabetes Mellitus
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.
- Trial name
- NCT00432276
- Testing
- Alogliptin, Pioglitazone, Metformin
- Where
- 86 sites in United States
- Volunteers
- 803 people
- Sponsor
- Takeda
Type 2 Diabetes, PreDiabetes
Behavioral Economics for Activity Motivation in Adolescents (BEAM)
There is an urgent need to engineer targeted physical activity interventions that are effective and scalable for obese adolescents and young adults (AYA) with type 2 diabetes (T2D), who often have very low levels of physical…
- Conditions
- Type 2 Diabetes, PreDiabetes, Insulin Resistance, Polycystic Ovary Syndrome
- Trial name
- NCT04874415
- Testing
- 1RLD, 1RLW, 1RGD
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Pittsburgh
Diabetes Mellitus, Type 2, Metabolic Syndrome X
Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness
Cilostazol is an antiplatelet agent used to reduce the symptoms of intermittent claudication. Cilostazol inhibits phosphodiesterase III (PDE III), which causes it to be a vasodilator and inhibitor of platelet aggregation.
- Trial name
- NCT00573950
- Testing
- cilostazol
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Korea University Anam Hospital
Diabetes Mellitus
Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.
The purpose of this study is to compare the efficacy of Alogliptin, once daily (QD), taken by itself and with pioglitazone on postprandial lipid measures in type 2 diabetes.
- Trial name
- NCT00655863
- Testing
- Alogliptin and Pioglitazone, Alogliptin
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 71 people
- Sponsor
- Takeda
Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome
Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2
The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have…
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome, Type 2 Diabetes
- Trial name
- DMMETCOV19 (NCT04626089)
- Testing
- metformin glycinate
- Where
- Mexico
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Diabetes Mellitus
Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.
The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and glimepiride combination therapy compared to glimepiride monotherapy in subjects with Type 2 Diabetes.
- Trial name
- NCT00770952
- Testing
- Pioglitazone and Glimepiride, Glimepiride
- Where
- 17 sites in Germany
- Volunteers
- 91 people
- Sponsor
- Takeda
Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease
Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease
This is a prospective, randomized, open-label, parallel-controlled clinical trial to evaluate the efficacy and safety of targeted IL-17A inhibition with secukinumab on cardiovascular and renal endpoints in 100 patients with…
- Conditions
- Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, Coronary Artery Disease
- Trial name
- NCT07704190
- Testing
- Secukinumab (75 mg), Standard Medical Therapy
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Obesity, Diabetes Mellitus, Type 2
Enteroendocrine Hormonal Response After the Ingestion of Cola Beverages With Sucrose and Non-nutritive Sweeteners
Introduction: The consumption of non-nutritive sweeteners (NNS) has been increasing in recent years, as an alternative to replace sugars and reduce the additional intake of carbohydrates, with the idea of reducing the risk of…
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Metabolic Syndrome
- Trial name
- NCT05654285
- Testing
- Cola beverage with aspartame and acesulfame K, Cola beverage with sucrose and stevia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospital Infantil de Mexico Federico Gomez